Loading
A phase 1 trial of Eganelisib run by Stelexis BioSciences, now recruiting.
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS is a phase 1 interventional study registered as NCT06533761 by Stelexis BioSciences, with 105 participants planned, started 2025-04-28. Conditions recorded: AML, Adult and MDS. Interventions recorded: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine and Azacitadine (AZA).
Shares Stelexis BioSciences, Eganelisib, Acute myeloid leukaemia and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/